# A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

> **NCT06655311** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 56 (actual)

## Conditions studied

- Healthy
- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Enlicitide Chloride
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06655311
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-30
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-01-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06655311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06655311, "A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06655311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*